Biosceptreinternational Limited Is A Biopharmaceutical Company Based In Cambridgeukwith Research Operations In Sydneyaustraliafounded In 201 Thecompany Specializes In Innovativecancer Therapiesparticularly Through Its Proprietary Bridgecara C Systemthis System Integrates Nfp2X7 Targeted Technology With Chimeric Antigen Receptorcart Cell Therapy And Multipletargeted Antibodies To Develop Universal Car T Systems Aimed At Treating Various Malignancies Thebridgecara C System Is Designed To Address Both Solid And Liquid Tumors By Utilizing Car T Cells And Antibodies To Target Specific Cancer Markersbiosceptreis Also Engaged In Therapeutic Development Programs Focusing On Basal Cell Carcinomaskin Cancersand Other Malignanciesemploying Antibody Based Therapies And Topical Formulationsadditionallythecompany Is Involved In Creating Diagnostic Tools For Cancer Detection And Monitoringwith A Commitment To Improving Outcomes For Cancer Patients Globallybiosceptrecollaborates With Research Institutes And Experts To Advanceits Clinical Programs
